ArticleBMC cancer2026
Machine learning-based radiopathomics ensemble model for predicting multiple molecular subtypes of adult diffuse glioma: a multicenter retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIDH and TERTp mutations serve as key molecular markers in glioma, closely associated with tumor clinical behavior, treatment response, and patient survival. Precise identification of molecular subtypes facilitates improved clinical risk stratification. This study aims to develop an integrated radiomics and pathomics model for the rapid classification of glioma molecular subtypes.
methodsThis multi-center retrospective study enrolled 434 adult patients with diffuse glioma from three independent centers. Radiomics features were extracted from preoperative MRI sequences, and pathomics features were extracted from regions of interest delineated on whole-slide images. Following feature selection, five distinct machine learning algorithms were employed to build individual radiomics and pathomics models for the binary classification of IDH and TERT promoter (TERTp) status, as well as for a four-class molecular subtype classification. The best-performing algorithm for each task was subsequently selected to construct a stacking model. Model classification performance was evaluated using receiver operating characteristic (ROC) curves and the area under the curve (AUC).
resultsFor the binary classification of IDH mutation status, the stacking model integrating radiomics and pathomics achieved AUCs of 0.850 in validation set and 0.852 in external test set. For TERTp mutation status prediction, the stacking model yielded AUCs of 0.766 (validation) and 0.770 (external test). In predicting the four-class molecular subtypes combining IDH and TERTp status, the stacking model demonstrated micro-AUC/macro-AUC values of 0.835/0.824 in validation set and 0.827/0.815 in external test set, outperforming the predictive performance of the TERTp-only model.
conclusionsStacking model based on Radiopathomics can rapidly predict multi-class molecular subtypes of glioma, providing robust support for risk stratification and management in patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.